812812_supplemental_tables for Recalls and Premarket Review Systems for High-Risk Medical Devices in Japan by Motoko Nakayama, Shiro Tanaka, Shota Hamada, Takahiro Uchida, and Koji Kawakami in Therapeutic Innovation & Regulatory Science</p
Supplemental material, Supplemental_tables_1_and_2 for Adverse Drug Events as a Reason for Adult Hos...
For drugs that are intended to fill unmet medical needs, such as the treatment of rare diseases or a...
<p>Supplemental material, Supplemental Method and Tables for Age-related differences in the rate and...
Supplemental_Table_S1 for Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy...
Supplemental_Table_S2 for Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy...
Supplemental Material, Supplemental_Table for Health Technology Assessment in Japan: A Pharmaceutica...
<p> Supplemental Material, Table_S1 for Comparison of Serious Adverse Event Profiles Among...
The Pharmaceuticals and Medical Devices Agency (PMDA) has conducted many pharmacoepidemiological stu...
<p> Supplemental Material, Table_S2 for Comparison of Serious Adverse Event Profiles Among...
<p> Supplemental Material, Table_S3 for Comparison of Serious Adverse Event Profiles Among...
Supplemental Material, HTA_Survey_Form for Health Technology Assessment in Japan: A Pharmaceutical I...
Supplemental material, fig_1_(1) for Exploratory analysis of comparative clinical trials used for ma...
Takeda Chemical Industries, Ltd. has established a comprehensive adverse events ( A E) management s...
The Ministry of Health, Labor and Welfare (MHLW or Koseirodosho in Japanese) is in charge of the pha...
Background:Japanese Clinical Research Act was enacted in April 2017 and this Act covers clinical tri...
Supplemental material, Supplemental_tables_1_and_2 for Adverse Drug Events as a Reason for Adult Hos...
For drugs that are intended to fill unmet medical needs, such as the treatment of rare diseases or a...
<p>Supplemental material, Supplemental Method and Tables for Age-related differences in the rate and...
Supplemental_Table_S1 for Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy...
Supplemental_Table_S2 for Risk of Extrapyramidal Syndromes Associated With Psychotropic Polypharmacy...
Supplemental Material, Supplemental_Table for Health Technology Assessment in Japan: A Pharmaceutica...
<p> Supplemental Material, Table_S1 for Comparison of Serious Adverse Event Profiles Among...
The Pharmaceuticals and Medical Devices Agency (PMDA) has conducted many pharmacoepidemiological stu...
<p> Supplemental Material, Table_S2 for Comparison of Serious Adverse Event Profiles Among...
<p> Supplemental Material, Table_S3 for Comparison of Serious Adverse Event Profiles Among...
Supplemental Material, HTA_Survey_Form for Health Technology Assessment in Japan: A Pharmaceutical I...
Supplemental material, fig_1_(1) for Exploratory analysis of comparative clinical trials used for ma...
Takeda Chemical Industries, Ltd. has established a comprehensive adverse events ( A E) management s...
The Ministry of Health, Labor and Welfare (MHLW or Koseirodosho in Japanese) is in charge of the pha...
Background:Japanese Clinical Research Act was enacted in April 2017 and this Act covers clinical tri...
Supplemental material, Supplemental_tables_1_and_2 for Adverse Drug Events as a Reason for Adult Hos...
For drugs that are intended to fill unmet medical needs, such as the treatment of rare diseases or a...
<p>Supplemental material, Supplemental Method and Tables for Age-related differences in the rate and...